669713-32fa7170-c5f0-43fd-977a-ab32fd01426d
Position
Vice President of Market Access
Bio
lex is Vice President of Market Access at Galapagos NV, a Belgo-Dutch company that develops therapies with proprietary, novel modes-of-action. Here Alex is leading the build-out of the global value and access function, helping to shape the pipeline of future products, and working with health care stakeholders to ensure that value is captured for patients and society from the medications Galapagos brings to regulatory approval. Galapagos is a leader in the frontiers of new science for patients with rheumatoid arthritis, cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF). Prior to Galapagos, Alex was Head of Global Value, Access, & Pricing at Incyte Corporation, a innovative biotechnology company focusing on oncology drug development. He was responsible for developing and implementing global market access, pricing and reimbursement strategy, including health economics and outcomes research support for Incyte. Prior to Incyte, Alex led a strategy market access practice in San Francisco with GfK. He was primarily focused on helping biopharmaceutical companies to better understand value drivers for pipeline assets, market access strategy, pricing and evaluation of new technologies, and crafting compelling value messaging platforms for new technologies. He is considered an expert concerning methodologies to drive commercial value of strategic and market access activities for biopharmaceuticals and companion diagnostics. Alex regularly speaks at conferences and has published papers, posters and abstracts on various pricing, access, and health economic themes, including: The Institute of Medicine National Cancer Policy Forum, The Institute of Medicine’s Health Care Services board, Regional Medicare Caucuses, State Medical Society Meetings, The American Society of Hematology, ISPOR, the National Venture Capital Association, and The Association of Community Cancer Centers. He was also a strategic advisor to ASCO’s taskforce to establish a value algorithm to assess new technologies in cancer care. He also acted as an advisor to the MED project for innovative risk-sharing models in the USA.
Interests
None yet.